[{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyundai Bioscience Leads in the Repurposing of Niclosamide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemotherapy May Be Completed Within 8 Days with Two Doses of Polytaxel, an Innovative Anticancer Drug from South Korea's Biotech Firm","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyundai Bioscience Announced Positive Phase 2 Clinical Study Results of The Global Blockbuster Candidate for The Covid-19 Antiviral Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyundai Bioscience Announces that \"Xafty is the only Antiviral that can be Immediately Used for the Treatment of Dengue Fever\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Hyundai Bioscience
Xafty is a novel broad-spectrum antiviral with niclosamide's mechanism that eliminates viruses that infiltrated cells and can solve RNA virus infections, capable of treating both COVID-19 and Dengue fever or Dengue virus infection.
Xafty's active ingredient, niclosamide's mechanism is to remove viruses by activating cell autophagy, it is being investigated for COVID-19 as an antiviral drug candidate.
Polytaxel is loaded with docetaxel as its active pharmaceutical ingredient, which is known as one of the major chemotherapy drugs. This chemotherapy is a patient-centered treatment that focuses on controlling toxicity of anticancer drug.
The paper published in SCI journal reveals the mechanism of repurposed Niclosamide. This is the first time that a paper demonstrating drug repurposing through various study results has been published in an SCI-level international journal.